One of the longest, established, privately held biotech companies, founded in 1978.
Leading global provider of high-quality raw materials to the in-vitro diagnostic industry and research laboratories.
ISO 13485:2016 registered.
KEY CAPABILITIES
First to market proteins and monoclonal antibodies for the new emerging viruses, eg. Dengue, Chikungunya and Zika, Sars, Covid -19 and VEEV virus.
Wide range of well-established products for chemiluminscence, ELISA, lateral flow and other immunoassay formats.
Custom manufacture of antibodies and recombinant antigens under ISO 13485:2016 conditions
OUR GOAL
To maintain our position as the leading global provider of high-quality and esoteric biological raw materials to the in-vitro diagnostic industry.
To enable our customers to bring ground-breaking technology to the market faster allowing cost-effective and efficient patient management at the point of impact.
